WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock Ownership - Who owns Spyre Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Spyre Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jeffrey W. AlbersDirector2024-11-066,700$36.76
$246.31kSell
Jeffrey W. AlbersDirector2024-10-25300$36.43
$10.93kSell
Scott L. BurrowsChief Financial Officer2024-09-0318,531$28.17
$522.07kSell
Cameron TurtleChief Executive Officer2024-02-15400$9.82
$3.93kBuy

1 of 1

SYRE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SYRE insiders and whales buy or sell their stock.

SYRE Shareholders

What type of owners hold Spyre Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC27.81%14,301,760$387.29MInsider
Fmr LLC14.82%7,623,881$206.45MInstitution
Fairmount Funds Management LLC7.81%4,018,101$108.81MInstitution
Rtw Investments LP6.34%3,258,360$88.24MInstitution
Baker Bros Advisors LP6.02%3,094,590$83.80MInsider
Perceptive Advisors LLC5.59%2,872,547$77.79MInstitution
Orbimed Advisors LLC5.50%2,829,748$76.63MInsider
Vr Adviser LLC5.22%2,685,448$72.72MInstitution
Blackrock Inc 15.18%2,663,147$72.12MInstitution
Vanguard Group Inc4.89%2,515,920$68.13MInstitution

1 of 3

SYRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SYRE66.62%33.38%Net SellingNet Selling
DAWN58.93%41.07%Net SellingNet Selling
BCYC58.57%40.91%Net SellingNet Selling
MDXG45.03%54.97%Net Buying
SPRY41.35%58.65%Net SellingNet Selling
View Top Biotech Stocks

Spyre Therapeutics Stock Ownership FAQ

Who owns Spyre Therapeutics?

Spyre Therapeutics (NASDAQ: SYRE) is owned by 99.90% institutional shareholders, 50.05% Spyre Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Spyre Therapeutics shareholder, owning 14.30M shares representing 27.81% of the company. Fairmount Funds Management LLC's Spyre Therapeutics shares are currently valued at $387.29M.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.